Fresh off slashing 10,000 jobs at Health and Human Services and then acknowledging he had to rehire those mistakenly fired, ...

A change in the monetary system presages a commodity bull market. Not only gold, but commodities generally will likely respond positively to what’s underway, advises Adrian Day, editor of Global ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent.

Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...